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Abstract 24 
Background: Current diagnostic tests are ineffective at identifying the aetiological pathogen 25 
in hospitalised adults with lower respiratory tract infection (LRTI). The association of 26 
pneumococcal colonisation with disease has been suggested as a means to increase 27 
diagnostic precision. We compared pneumococcal colonisation rate and density of nasal 28 
pneumococcal colonisation by a) classical culture and b) quantitative real time lytA 29 
Polymerase Chain Reaction (qPCR) in patients admitted to hospital in the UK with LRTI 30 
compared to control patients. 31 
Methods: 826 patients were screened for inclusion in this prospective case-control study. 38 32 
patients were recruited, 19 with confirmed LRTI and 19 controls with another diagnosis. 33 
Nasal wash (NW) was collected at the time of recruitment.  34 
Results: Pneumococcal colonisation was detected in 1 LRTI patient and 3 controls (p=0.6) 35 
by classical culture. Using qPCR pneumococcal colonisation was detected in 10 LRTI 36 
patients and 8 controls (p=0.5). Antibiotic usage prior to sampling was significantly higher in 37 
the LRTI than control group 19 v. 3 (p<0.001).  Using a clinically relevant cut-off of >8000 38 
copies/ml on qPCR pneumococcal colonisation was found in 3 LRTI patients and 4 controls 39 
(p > 0.05). 40 
Conclusions: We conclude that neither prevalence nor density of nasal pneumococcal 41 
colonisation (by culture and qPCR) can be used as a method of microbiological diagnosis in 42 
hospitalised adults with LRTI in the UK. A community based study recruiting patients prior to 43 
antibiotic therapy may be a useful future step. 44 
 45 
 46 
 47 
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Introduction 48 
Recent studies suggest that detection and quantification of nasal pneumococcus by 49 
quantitative real time lytA Polymerase Chain Reaction (qPCR) could be used to identify 50 
pneumococcus as the aetiological pathogen in adults with pneumonia [1] and could be 51 
useful as a disease severity marker [2]. In that study, South African patients with community 52 
acquired pneumonia (CAP) were more frequently colonised than controls using classical 53 
culture (44.9 v. 11.7%)  and qPCR (62.8 v. 19.8%) and, in addition, patients with 54 
pneumococcal CAP were also noted to have higher colonisation density than asymptomatic 55 
controls [1]. By applying a cut off of 8000 copies/ml to the qPCR data Albrich et al [1] found 56 
that 52.5% of patients were considered to have pneumococcal CAP, compared with 27.1% 57 
diagnosed using standard tests.  58 
 59 
The association of pneumonia and pneumococcal colonisation has been previously noted in 60 
children, in whom those with radiological pneumonia were more frequently colonised with 61 
pneumococci than those without [3] and had higher density colonisation than those with 62 
bronchitis or without disease [4]. In contrast, in the elderly very low colonisation rates have 63 
been shown; 0.3% in pneumococcal vaccine naive hospitalised Australians (by classical 64 
culture) [5] (of which 10 had respiratory infection) and 2.3% in a Portuguese community 65 
cohort [6]. In developed countries, pneumococcal colonisation rates in healthy adults are 66 
between 1 - 18%, and are affected by age, immune status, antibiotic use, household 67 
composition and contact with children [7, 8]. There are no published data on pneumococcal 68 
colonisation in hospitalised patients with respiratory infection in the UK. 69 
 70 
We therefore aimed to determine the rate and density of pneumococcal colonisation by a) 71 
classical culture and b) qPCR in hospitalised adult patients with LRTI when compared with 72 
age and gender-matched controls in a developed country setting.  73 
 74 
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Materials and Methods 75 
Screening and Recruitment 76 
We recruited hospitalised adults with LRTI at the Royal Liverpool and Broadgreen University 77 
Hospital from January - July 2013 within 72 hours (hrs) of admission. The syndrome of LRTI 78 
was defined as; symptoms of respiratory infection with clinical signs +/- radiological 79 
consolidation; therefore meeting a British Thoracic Society (BTS) definition of pneumonia as 80 
used in community (GP) practice. Clinical signs of LRTI included ≥2 of: cough, 81 
breathlessness, pleuritic chest pain, fever, increased or new sputum production. Exclusion 82 
criteria were: patients with infective or non-infective exacerbations of chronic obstructive 83 
pulmonary disease (IECOPD), asthma or bronchiectasis (without radiological consolidation), 84 
aspiration pneumonia, oxygen saturations <86% on air, suspected tuberculosis (TB) and 85 
neutropenia. Patients with IECOPD were excluded as exacerbations are known to commonly 86 
be due to viruses (up to 60%) [9, 10], Haemophilus influenzae (up to 33%) [11] and 87 
Moraxella catarralis (around 10%) [12] rather than pneumococcus. Patients who had been a 88 
hospital inpatient for ≥72 hrs or had recently been discharged from hospital ≤14 days before 89 
were excluded since it is likely their nasal flora would have altered due to hospital 90 
exposures. Patients with oxygen saturations <86% on air were excluded since it was felt 91 
unsafe to remove their oxygen in order to perform a nasal wash (NW).  92 
A carefully selected control group of hospitalised patients with no signs of respiratory 93 
infection were recruited within 7 days (where possible or as soon after as possible) of the 94 
LRTI patient. The control group were matched for age (within 10 years of the LRTI patient) 95 
and gender. Exclusion criteria were: oxygen saturations <86% on air, neutropenia, ≥ 7 days 96 
after admission and recent hospital discharge ≤14 days.  97 
The study team were in regular communication with the hospital capacity team, the ward 98 
based case managers, nursing and medical co-ordinators in accident and emergency (A&E), 99 
the acute medical admissions unit (AMAU) and the respiratory wards from Monday to 100 
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Thursday. Through regular education, information dissemination events, and daily interaction 101 
with the study team, key staff were made aware of the study and its aims, objectives, and 102 
potential participants. A list of potential participants was generated on a daily basis in 103 
combination with these personnel. To recruit LRTI patients we targeted screening to AMAU, 104 
respiratory and infectious disease wards, for control participants we targeted surgical wards. 105 
Patient eligibility was confirmed by review of the medical records; with permission of the 106 
attending team, patient consent was sought prior to recruitment. Baseline clinical data of 107 
age, gender, history of presenting complaint, past medical history, vaccination history, 108 
antibiotic prescription, and contact with children (defined as at least alternate day contact 109 
with children aged ≤ 10yrs) were recorded. NW and urine samples were collected within 12 110 
hours of recruitment. The study was approved by Liverpool East, North-west NHS Research 111 
Ethics Committee (12/NW/0713) and registered with ClinicalTrials.gov (NCT01861184). 112 
Sampling 113 
NW was collected on the day of recruitment with a maximum of 20 mls of normal saline 114 
instilled into the nasopharynx as previously described[13, 14]. A minimum of 5 mls of normal 115 
saline was recovered and processed in all cases. Briefly, samples were immediately 116 
centrifuged at high speed (3345 x g) to obtain a bacterial pellet [14]. Pellets were 117 
resuspended in 100µl of skimmed-milk tryptone glucose glycerol (STGG) medium and the 118 
total volume of the suspension was determined. Samples were then serially diluted on blood 119 
agar and CFUs/mL of NW were determined the next day. In a subset of samples that 120 
exceeded 7 mls a proportion of the sample (3 – 5 mls) was removed and centrifuged at 836 121 
x g to obtain cellular material after which the supernatant was re-added to the rest of the 122 
sample for the high speed spin.  123 
DNA extraction and qPCR 124 
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DNA was extracted from 200 µl of the NW bacterial pellet stored in STGG using the QIAamp 125 
DNA mini kit and the Centers for Disease Control protocol [15]. Briefly, the pellet was 126 
resuspended in 200 µl TE buffer containing 0.04 g/ml lysozyme and 75 U/ml mutanolysin 127 
(Sigma) and incubated at 37°C for 1 hr. Following incubation, 20 µl of proteinase K and 200 128 
µl of Buffer AL were added to the sample which was vortexed and then incubated at 56°C for 129 
30 min. The sample was then centrifuged briefly and 260 µl of ethanol was added. All 130 
subsequent steps followed the manufacturer’s instructions. DNA was eluted in 100 µl of 131 
QIAGEN elution buffer and stored at -20°C. 132 
Colonisation density was determined by targeting the pneumococcal autolysin lytA gene 133 
[16]. A no-template control, a negative extraction control (parallel extraction of TE buffer) and 134 
a S. pneumoniae (BHN418) positive control were included in each run. DNA was amplified 135 
with the Mx3005P system (Stratagene) and data was analysed using the instrument 136 
software. A sample was considered positive if both duplicates had a cycle threshold (CT) 137 
value below a mean 35. Values of >8000 copies/ml were considered clinically relevant as 138 
per Albrich and colleagues [1].  139 
Binax 140 
An immunochromatographic membrane test (ICT) (BinaxNOW Streptococcus pneumoniae; 141 
Binax) was performed on all patient’s unconcentrated urine specimens, according to the 142 
manufacturer’s recommendations. 143 
 144 
 145 
 146 
 147 
 148 
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Results 149 
Screening and recruitment 150 
We screened 826 patients and recruited 19 LRTI and 19 control (age, gender and season 151 
matched) patients. 217 were ‘potential’ LRTI patients, of which 198 were not eligible (Figure 152 
1). 58 patients did not have a syndrome of LRTI (acute exacerbation [AE] COPD n=22, AE 153 
bronchiectasis n = 5, AE asthma n=3, AE pulmonary fibrosis n= 1 and alternative diagnoses 154 
including pulmonary embolus (PE), congestive cardiac failure (CCF), sepsis of unknown 155 
cause and adult acute respiratory distress syndrome (ARDS) n = 30), 36 patients did not 156 
have capacity to consent (predominately due to dementia or acute delirium), 48 patients 157 
were identified >72 hours after admission and 17 after a recent hospital discharge ≤14 days 158 
before, 20 patients declined to participate and 2 ‘next of kin’ refused permission for their 159 
relative to participate, 10 oxygen saturations <86% on air, 12 aspiration pneumonia, 14 were 160 
excluded for other reasons. 161 
We planned to recruit 100 patients to each arm of the study, but stopped recruiting on the 162 
grounds of futility after interim analysis noted 100% antibiotic usage prior to recruitment in 163 
the LRTI group and low rates of colonisation (on culture) and due to high screen failure rate 164 
(778/816, 95.4%). Recruiting age matched controls was difficult, especially for the younger 165 
LRTI patients (aged 36 - 46 yrs old). In 9 cases, the time between the recruitment of the 166 
LRTI patient and control was >7 days (range 9 - 43). We know from our Experimental 167 
Human Pneumococcal Colonisation (EHPC) studies that antibiotic usage terminates 168 
pneumococcal colonisation, meaning that continued recruitment in this population was 169 
unethical.  170 
Sampling: Rate of colonisation  171 
All patients were successful at providing a nasal sample. One patient was unable to replicate 172 
the NW technique (as per protocol) and therefore had a nasopharyngeal swab instead. NW 173 
volumes were not significantly different between LRTI patients and controls (Table 1). 174 
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Pneumococcal colonisation was detected using classical microbiology in 1 LRTI patient and 175 
3 controls (p=0.6). Using qPCR 10 LRTI patients and 8 controls were positive (p=0.516) 176 
[Table 2)]. One of the controls was positive for colonisation by culture but considered 177 
negative by qPCR as the CT value was >35.  178 
Sampling: Density of colonisation by qPCR 179 
For qPCR a cut off value of >8000 copies/ml was used to define clinical relevance [1]. In our 180 
study, 3 LRTI patients and 4 controls had values >8000 copies/ml. Of the 3 LRTI patients, 181 
only 1 was culture positive; of the 4 controls, 2 were culture positive (Table 2). Of the 4 182 
patients overall who were culture positive, 3 had >8000 copies/ml, 1 in the LRTI and 2 in the 183 
control group. 184 
Clinical data 185 
Antibiotic usage prior to sampling was significantly higher in LRTI patients than controls 19 v. 186 
3 (p<0.001). Radiological consolidation was present in 7 out of 19 LRTI patients; only 2 out 187 
of 38 urine samples were positive using BinaxNOW. None of the LRTI patients recruited 188 
were pneumococcal sputum or blood culture positive. There were no statistical differences 189 
between the groups with regards to smoking, contact with children age <10yrs old or 23 PPV 190 
pneumovax vaccination (Table 1).  191 
 192 
 193 
 194 
 195 
 196 
 197 
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Discussion 198 
The anticipated high rate of pneumococcal colonisation (by culture +/- qPCR) in the LRTI 199 
group was not found, given that antibiotic usage (pre-admission/pre-recruitment) was 200 
significantly different between LRTI and control groups, with all LRTI patients having 201 
received at least 2 doses prior to NW, this is likely to have resulted in culture negativity. 202 
However we also found no significant difference in colonisation rates using qPCR and 203 
colonisation density between the LRTI and control groups. There was also no significant 204 
difference in colonisation rates in polysaccharide vaccinated (23 PPV Pneumovax) and 205 
unvaccinated patients, consistent with previous literature reporting that the vaccine does not 206 
protect against colonisation [17, 18]. 207 
Large numbers of patients were referred as ‘potential LRTI’. Alternative diagnoses such as 208 
PE, CCF, non-infective exacerbation of pulmonary fibrosis, sepsis of unknown cause and 209 
aspiration pneumonia were common. This diagnostic imprecision has important implications 210 
for the use of NW as a diagnostic technique since it would lead to many inappropriate 211 
samples being collected. We have previously demonstrated that confusion is common in 212 
LRTI patients (>20%) [19]. LRTI rates increase with age (63% CAP admissions were aged 213 
>65 and 25% ≥85yrs old) [20] as do rates of comorbidities (including dementia), therefore 214 
recent hospital admission is also common.  215 
The main strength of this study is the large number of screened patients; the LRTI patients 216 
are well phenotyped and the controls are matched in age, gender and time with similar 217 
smoking habits, 23 PPV pneumovax vaccination rates and child contact. Our cohort was not 218 
‘CAP’ by strict definition of radiological consolidation, instead a broad study group of LRTI 219 
was chosen due to its clinical relevance in UK hospital practice and admissions, making 220 
these results very generalisable. Nationally, GP antibiotic prescribing for LRTI is very high, 221 
but lower for clinically diagnosed CAP (due to usual immediate hospitalisation) [21].  222 
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Accurately diagnosing pneumonia is challenging; inter-doctor variability in reporting of 223 
radiological pneumonia is common [22]. Studies of patients that have radiological 224 
pneumonia as an inclusion criterion may be less applicable to everyday hospital medicine. 225 
LRTI may be a more useful term for this clinical syndrome, particularly in instances where 226 
guidelines suggest clinical rather than radiological diagnosis [20]. Liverpool is in the North-227 
west of England, and has the secodrnd highest LRTI rate (age standardised episodes/1000 228 
person years) and the third highest CAP rate nationally. [21] It is therefore an ideal area for 229 
recruiting to respiratory infection studies, although community antibiotic prescription rates 230 
are high. The Royal Liverpool hospital has ~1400 admissions per year that are coded as 231 
‘pneumonia’, approximately 20% of these cases are not community acquired or have no 232 
radiological features of pneumonia.  233 
Limitations of the study include that this is a single centre study which may reduce the 234 
generalisability of the results specifically in areas where community antibiotic prescription 235 
rates are lower, that we were unable to fully recruit to the study despite high numbers 236 
screened and that the NW technique, rather than nasopharyngeal swab, for pneumococcal 237 
isolation may not have been ideal in this elderly population, since the research nurses noted 238 
poor technique and lower yields than in the cohort of healthy volunteers in which we 239 
commonly use this technique (data not shown). Nevertheless, patient comfort is higher [23] 240 
and sensitivity for colonisation density is very high [24]. We know from our Experimental 241 
Human Pneumococcal Colonisation (EHPC) studies that antibiotic usage terminates 242 
pneumococcal colonisation; after interim analysis noted 100% antibiotic usage in the LRTI 243 
group prior to recruitment and low rates of colonisation (on culture), the study was stopped 244 
as continued recruitment in this population was unethical. 245 
Previous studies have shown colonisation rates of 44.9% and 62.8% in patients with 246 
radiologically confirmed CAP compared to 11.7% and 19.8% in controls, by culture and 247 
qPCR respectively [1]; in comparison we detected colonisation of 5% and 15.8%  (>8000 248 
copies/ml) in patients with LRTI and 15.8% and 21.0%  (>8000 copies/ml)  in controls. We 249 
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therefore noted high rates of PCR positivity in both groups and low rates of culture positivity 250 
in our LRTI patients compared with the CAP patients in this previous study. The differences 251 
between the two studies may be due to the fact that our patient cohort was considerably 252 
older (64.5 v. 38.4 yrs old) [1], had low rates of radiologically confirmed pneumonia (36.8%), 253 
high rates of prior antibiotic treatment, high rates of contact with children and are presumed 254 
HIV uninfected (overall HIV incidence is low in Liverpool - 15 per 100000, with a prevalence 255 
of 0.17% in 2011 [unpublished local data]). Previously in Liverpool we found natural 256 
colonisation rates in healthy non-smoking volunteers of 10% by classical culture (25/249, 257 
age 23 yrs old [SD ±5.7]) [unpublished data]. The higher rate (15.8%) in this cohort may be 258 
related to their high rates of contact with children and smoking history. 259 
qPCR can deliver results within a few hours (usually 3-6hrs) and could impact the critical 260 
phase of early clinical care [25], however it does not distinguish between viable (live) and 261 
non-viable (dead) bacteria or determine whether the bacteria is a pathogen or a coloniser 262 
[26, 27]. Specificity can also be an issue with qPCR and there have been concerns that lytA 263 
may not discriminate between S. pneumoniae and S. viridans, however lytA is currently the 264 
most widely used target gene for pneumococcus and we have previously shown that our 265 
assay specificity [24] is in line with that reported by others [16].  266 
Within this cohort all LRTI patients had taken antibiotics prior to sampling, which likely 267 
accounts for the higher positivity rate of qPCR over culture. Prior antibiotic treatment can 268 
lower plasma and pleural fluid PCR loads [28] as well as sputum and blood culture positivity. 269 
It is not known how rapidly pneumococcus will be undetectable by qPCR in the NW of those 270 
previously colonised with pneumococcus after antibiotic therapy.  271 
Albrich and colleagues suggest that a density of 103-104 may be the critical density at which 272 
colonisation leads to infection [1]; however we have found densities as high or higher in our 273 
cohort of healthy volunteers after experimental colonisation without infection [24, 29]. 274 
Colonisation density was not different in LRTI and controls, we also found high mean 275 
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densities ≥103 in those without infection (n = 4 controls). It is possible therefore that if 276 
colonisation is dense and in the setting of the correct clinical syndrome then the 277 
pneumococcus is a likely pathogen. Again an important difference between the two study 278 
groups may be HIV infection status. Only 10.5% (2/19) of our LRTI group were Binax 279 
positive compared to 72.7% in patients with non-bacteraemic CAP in another study [1]. 280 
Binax results remain positive for at least 7 days after the initiation of antibiotic treatment [30]; 281 
notably our urine samples were taken up to 72hrs after admission but often several days 282 
after antibiotics had been started. Previous antibiotic therapy has been noted to decrease 283 
culture and qPCR positivity by up to 50% [1]. 284 
 285 
Conclusion 286 
We have shown that pneumococcal colonisation (assessed by culture and qPCR) cannot be 287 
used as a method of diagnosis in pneumococcal blood culture negative hospitalised adults 288 
with LRTI in the UK, since such patients have already received community antibiotics and 289 
the laboratory test is non-discriminatory. Further, the number of adults tested for ‘potential 290 
LRTI’ on screening would be impracticable in terms of staff resource. A community based 291 
study recruiting patients prior to antibiotic therapy may however be a useful future step. 292 
 293 
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 442 
Figure legends: 443 
Figure 1: Screening and recruitment flowchart. Reasons for non-recruitment for lower 444 
respiratory tract infection (LRTI) patients are detailed. Total no. screened n = 826. Note 445 
multiple reasons for non-recruitment per patient were possible. 446 
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Tables: 447 
Table 1: Baseline demographics, antibiotic Status, nasal wash volume returned and 448 
evidence of pneumococcal disease investigation results of patients with lower respiratory 449 
tract infection (LRTI) and age and gender matched hospitalised controls.  450 
 451 
 LRTI (n=19) Control 
(n=19) 
p value 
Gender: Male n (%) 
 
9 (47.4) 9 (47.4) 1.000 * 
Age Years ± SD 
 
64.47 ± 
15.78 
64.58 ±14.50 0.954 β 
Smoker/ ex-smoker n (%) 
 
15 (78.9) 10 (52.6) 0.170 α 
23 PPV Pneumovax n (%) 
 
7 (36.8) 8 (42.1) 0.740 * 
Contact with children n (%) 
 
10 (52.6) 12 (63.2) 0.511 * 
Antibiotics at time of recruitment n (%) 
 
19 (100) 3 (15.8) 0.0001 α 
Nasal wash volume returned (ml) ± SD 
 
10.14 ± 3.14 10.36 ± 4.83 0.855 β 
Evidence of pneumococcal disease: Binax urine 
test positive n (%) 
2 (10.5) 0 (0) 0.486 α 
Evidence of pneumococcal disease: Blood or 
sputum culture positive n % 
0 (0) N/A N/A 
*Chi Square, β Mann Whitney U test, α Fisher’s Exact, SD standard deviation, PPV 452 
polysaccharide vaccine 453 
18 
 
Table 2: Pneumococcus identification (by culture, qPCR) and density (by qPCR) in patients 454 
with lower respiratory tract infection (LRTI) and age and gender matched hospitalised 455 
controls. 456 
Note low rates of culture positivity and high rates of qPCR positivity in both LRTI and control 457 
groups. 458 
 459 
 LRTI (n=19) Control (n=19) p value 
Culture positive n (%) 1 (5) 3 (15.8) 0.604 α 
qPCR positive n (%) at detection 
limit 
10 (52.6) 8 (42.1) 0.516 * 
Density (by qPCR) copies/ml 
(geometric mean) [95% CI] 
3066 [1225 – 7675] 2208 [244 – 19972] 0.408 β 
Clinically relevant density (by 
qPCR) >8000 copies/ml 
3 4 0.999 α 
α Fisher’s Exact, *Chi squared, β Mann Whitney U test, qPCR quantitative polymerase chain 460 
reaction 461 

